UTMB develops a universal vaccine platform that’s cheaper and shelf stable
Researchers at The University of Texas Medical Branch at Galveston have developed a less expensive way to produce vaccines that cuts the cost of vaccine production and storage by 80 percent without decreasing safety or effectiveness. The findings are currently available in EBioMedicine.
Vaccines are the most effective way to prevent and eradicate infectious diseases. Currently, many vaccines have to be manufactured in cell culture or eggs, which is expensive and carries the risk of contaminations. In addition, most vaccines must be kept refrigerated during the transportation from manufacturers to health care clinics. In tropical and subtropical regions, such cold storage requirements could contribute to more than 80 percent of the vaccine cost.
“The ability to eliminate cell culture or eggs and cold storage will change the process of vaccine development,” said UTMB’s Pei-Yong Shi, professor in the department of biochemistry and molecular biology. “Importantly, this vaccine technology could potentially serve as a universal platform for development of live-attenuated vaccines for many viral pathogens.”
To achieve these goals, the UTMB team engineered a live-attenuated Zika vaccine in the DNA form. Once the DNA is delivered into our body, it launches the vaccine in our cells, leading to antibody production and other protective immunity. With this production method, there is no need to manufacture the vaccine in cell culture or eggs at factories. Because DNA molecules are shelf stable, the vaccine will not expire at warm temperatures and could be stockpiled at room temperature for years.
Using UTMB’s Zika vaccine as a model, the research group showed that the DNA platform worked very efficiently in mice. After a single low dose, the DNA vaccine protected mice from Zika virus infection, mother-to-fetus transmission during pregnancy and male reproductive tract infection and damage.
“This is the first study to demonstrate that, after a single low dose, a DNA vaccine could induce saturated protective immunity,” Shi said. “We will continue testing this promising Zika vaccine platform and then apply the platform to other viruses.”
The Latest on: Vaccine production
via Google News
The Latest on: Vaccine production
- Coronavirus vaccine trials: Chinese volunteers recount their experienceson March 22, 2020 at 5:00 pm
it would still be some time before a vaccine was ready to go into mass production. Story continues “It may be available within six to nine months of starting clinical trials, he said. “So that would ...
- Who is leading the race to develop the coronavirus vaccine?on March 22, 2020 at 4:50 pm
If proven, the commission said, millions of vaccine doses could be produced at low costs in the company's existing production facilities. "The combination of mRNA science, disease understanding, ...
- In clinical trials and laboratories, the hunt is on to find vaccines and drugs to treat, prevent novel coronaviruson March 22, 2020 at 4:09 pm
The rapid spread of the COVID-19 virus has prompted medical researchers worldwide to go on the offense and look for vaccines and treatments. Bill Whitaker reports on some of the leading efforts. With ...
- Vaccine scientist: ‘Everything is so new in dealing with this coronavirus’on March 21, 2020 at 1:51 pm
Hanneke Schuitemaker, who is leading a team working on a Covid-19 vaccine, tells of the latest developments and what needs to be done now ...
- The physician whose 1964 vaccine beat back rubella is working to defeat the new coronaviruson March 21, 2020 at 5:14 am
A: One needs to prepare now—and I’m assuming that there will be a vaccine or multiple vaccines—for the production of large numbers of doses. Because that’s not something that you can do on your ...
- Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronaviruon March 21, 2020 at 4:12 am
rapid discovery to respond to emerging pandemic threats and manufacturing agility derived from the platform nature of mRNA vaccine design and production. Moderna has built a fully integrated ...
- Gaithersburg biotech gets green light for superbug therapy, explores COVID-19 vaccine productionon March 19, 2020 at 11:30 am
Adaptive Phage Therapeutics is developing a therapeutic for drug-resistant infections, aka superbugs. Here's what that means for the novel coronavirus pandemic — and what else the Gaithersburg firm is ...
- False claim: Coronavirus vaccine approved in Israel, set for mass production and distributionon March 18, 2020 at 3:18 pm
has been approved in Israel ( here) The image, posted on Facebook on March 14, 2020, makes the further claim that the vaccine is already being mass produced and should soon be available in the U.S.
- Europe Dominates Global Vaccine Productionon March 16, 2020 at 9:03 am
With a large proportion of the world's production, research and development activities located there, Europe is the global leader in vaccine production. The following infographic is based on Vaccines ...
via Bing News